Seoul Pharma Co., Ltd
Research Seoul Pharma Co., Ltd (018680.KQ) on Bullrun: market cap KRW 21.69B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker018680.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 21.69B
- Financial periodQ2 2026
- RevenueKRW 11.76B
- Net income-KRW 317.70M
- Free cash flowKRW 868.42M
- Gross margin61.0%
Valuation Snapshot
latest market cap is KRW 21.69B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 21.69B | n/a | n/a | n/a |
About Seoul Pharma Co., Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Seoul Pharma Co., Ltd's market cap?
Seoul Pharma Co., Ltd's market capitalization is KRW 21.69B.
What does Seoul Pharma Co., Ltd do?
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and menopausal syndrome.